Inovio Pharmaceuticals, Inc. (INO) Stock Analysis — Probabli.AI
AI-powered analysis for INO (Inovio Pharmaceuticals, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $1.46 · Market cap: $119.1M · AI outlook: Bullish
Inovio Pharmaceuticals is poised for significant growth due to its strong focus on DNA medicines, partnerships, recent regulatory progress, and its ability to meet earnings expectations. Analyst consensus signals strong confidence in the stock, supported by a robust pipeline targeting high-impact market segments. While there are risks, particularly with regulatory scrutiny and competition, the…
Probabilistic 1-Year Outlook
- Bull 45% · Neutral 35% · Bear 20%
- 1-year price estimates — P10: $1 / P50: $2 / P90: $7
- Inovio Pharmaceuticals has significant positive catalysts, including recent trial successes and funding, but faces risks such as regulatory delays and competition. Considering the high growth potential of its product…
5-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 5-year price estimates — P10: $2 / P50: $12 / P90: $25
SWOT Highlights
- Strength: Strong pipeline in high-demand areas such as oncology and infectious diseases.
- Strength: Successful track record in meeting and exceeding earnings expectations.
- Risk: High competition in the vaccine and oncology sectors.
- Risk: Dependent on regulatory approvals which are subject to delays.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
4 Wall Street analysts rate INO a BUY with a mean price target of $6.75.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
INO forecast details · INO sentiment details · INO insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.